NeisVac-C has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life. Persistence of serum bactericidal antibody, rather than immune memory, is now known to be a more appropriate correlate of long-term protection for serogroup C meningococcal disease. NeisVac-C was demonstrated to enhance responses to Haemophilus influenzae type b (Hib) polyribosylribitol phosphate when coadministered with Hib-tetanus toxoid conjugate vaccines. NeisVac-C also enhances tetanus toxid responses and a dose of NeisVac-C in older children induces responses similar to a dose of tetanus toxoid vaccine.
%0 Journal Article
%1 borrow_prevention_2009
%A Borrow, Ray
%A Findlow, Jamie
%D 2009
%J Expert Review of Vaccines
%K Adolescent, Adult Adult, Aged, Antibodies, Bacterial, Child, Conjugate, Haemophilus Humans, Immunologic Infant, Memory, Meningitis, Meningococcal Meningococcal, Middle Preschool, Tetanus Toxoid, Vaccines, Young
%N 3
%P 265--279
%R 10.1586/14760584.8.3.265
%T Prevention of meningococcal serogroup C disease by NeisVac-C
%U http://www.ncbi.nlm.nih.gov/pubmed/19249967
%V 8
%X NeisVac-C has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life. Persistence of serum bactericidal antibody, rather than immune memory, is now known to be a more appropriate correlate of long-term protection for serogroup C meningococcal disease. NeisVac-C was demonstrated to enhance responses to Haemophilus influenzae type b (Hib) polyribosylribitol phosphate when coadministered with Hib-tetanus toxoid conjugate vaccines. NeisVac-C also enhances tetanus toxid responses and a dose of NeisVac-C in older children induces responses similar to a dose of tetanus toxoid vaccine.
@article{borrow_prevention_2009,
abstract = {{NeisVac-C} has been demonstrated to be safe, immunogenic and efficacious when administered to infants, toddlers, older children and adults. It is one of the licensed meningococcal serogroup C conjugate vaccines and a single dose in infancy may be sufficient for protection until a booster dose is given in the second year of life. Persistence of serum bactericidal antibody, rather than immune memory, is now known to be a more appropriate correlate of long-term protection for serogroup C meningococcal disease. {NeisVac-C} was demonstrated to enhance responses to Haemophilus influenzae type b {(Hib)} polyribosylribitol phosphate when coadministered with Hib-tetanus toxoid conjugate vaccines. {NeisVac-C} also enhances tetanus toxid responses and a dose of {NeisVac-C} in older children induces responses similar to a dose of tetanus toxoid vaccine.},
added-at = {2011-03-11T10:05:34.000+0100},
author = {Borrow, Ray and Findlow, Jamie},
biburl = {https://www.bibsonomy.org/bibtex/2459c6456fc728527734d837b0805fd2f/jelias},
doi = {10.1586/14760584.8.3.265},
interhash = {1a539529f929f633906e97876ad5f4db},
intrahash = {459c6456fc728527734d837b0805fd2f},
issn = {1744-8395},
journal = {Expert Review of Vaccines},
keywords = {Adolescent, Adult Adult, Aged, Antibodies, Bacterial, Child, Conjugate, Haemophilus Humans, Immunologic Infant, Memory, Meningitis, Meningococcal Meningococcal, Middle Preschool, Tetanus Toxoid, Vaccines, Young},
month = mar,
note = {{PMID:} 19249967},
number = 3,
pages = {265--279},
timestamp = {2011-03-11T10:06:50.000+0100},
title = {Prevention of meningococcal serogroup C disease by {NeisVac-C}},
url = {http://www.ncbi.nlm.nih.gov/pubmed/19249967},
volume = 8,
year = 2009
}